knowledge -WSS

knowledge

author：leisure time 2025-09-28 14:50:05 - browse：9

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： FDA approves Eli Lilly ulcerative colitis treatment Omvoh

entertainment

WSS

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Eliminate the waiting period for sterilization covered by Medicaid

First Opinion Podcast: How to protect health care in times of war

Readout Newsletter: What happened with Sarepta's Duchenne data

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

hotspot

knowledge

hotspot

How one medical school became remarkably diverse

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Supreme Court strikes down use of affirmative action

Eliminate the waiting period for sterilization covered by Medicaid

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Drug repurposing or repositioning? The language matters

Medtronic CEO on promising devices for diabetes, hypertension

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Paying for Covid pills will soon shift to insurers

Wikipedia

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Oprah kicked off a national conversation on obesity. Let's have it

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Telehealth options flood the market as retailers push virtual care

Study says nonprofit hospitals fall short in charity care spending

Abortion pill Supreme Court ruling could impact entire drug industry

leisure time

entertainment

hotspot

explore